At ELECTRONICA, ITEN Present an Autonomous Asset Monitoring Solution Based on a 100µA.h Micro-Battery!
ITEN, the deep tech company, which just closed a financing round of 80M€ to become a key player in the manufacture of solid-state lithium-ion micro-batteries, shall take the opportunity of next ELECTRONICA exhibition to present a breakthrough in the way of powering autonomous embedded systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221110005719/en/
Ecofriendly and powerful soli-state micro-battery able to recharge in a few minutes. (Photo: ITEN)
When observing the battery-powered electronic solutions, ITEN came indeed to the following conclusions:
- A lot of electronic designs relies on very polluting coin cells, difficult to assemble on Printed Circuit Boards, costly to recycle and requiring periodic maintenance to replace the battery once empty.
- Depending on the countries, only 30 to 50% of such coin cells are effectively recycled.
- Autonomous embedded systems require less and less energy to operate; however, from time to time, the power supply must deliver high current pulses for instance to drive RF transceivers or actuators; therefore, most electronic designers must use oversized coin cells because such batteries are known to deliver only small currents.
From a battery standpoint, this means that a lower battery capacity could be used if the battery would be able to deliver the required power and could be recharged regularly.
This is precisely what ITEN shall demonstrate during ELECTRONICA: ITEN shall indeed present an autonomous asset monitoring solution, including sensors and a Bluetooth Low Energy (BLE) System-on-a-chip, and powered by the combination of an indoor photovoltaic cell from DRACULA Technologies (LAYERR Technology) and ITEN’s powerful rechargeable SMD micro-battery of only 100µA.h. The solution operating 24/7 can send data every 10 seconds during the day and every 4 to 5 minutes during the night (this frequency could be increased if using a 250µA.h micro-battery instead). By comparison, a coin cell of at least 100mA.h would be required to get the same operating conditions but with a limited lifetime.
By extension, similar designs could be used in applications like BLE asset tracking, BLE tags, beacons, and sensor data loggers.
On stand B4-120, ITEN shall also demo micro-batteries used as a back-up power supply to keep some clocks or microcontrollers active or to send maintenance alerts in case of failure of the main power source.
By doing so, ITEN clearly reassert their strategy to progressively replace most of the coin cells used worldwide by ecofriendly rechargeable SMD micro-batteries containing neither heavy metals, nor toxic materials, nor organic solvents and showing a carbon footprint 200 to 1000 times less compared to coin cells.
After 8 years of R&D, ITEN have been granted more than 200 patents worldwide. ITEN are an integrated device manufacturer, controlling the complete production chain from nanomaterial synthesis up to the battery packaging and test. Even with low capacities, ITEN micro-batteries can deliver power and high current pulses. They are a concrete response to electronics designers looking for ecofriendly alternatives to coin cells. In this respect, ITEN solutions fit in with the European Directive recommending getting rid of non-rechargeable batteries in all electronic system designs from year 2030.
ITEN is the leading company developing and manufacturing ecofriendly solid-state lithium-ion SMD micro batteries. Such micro batteries are rechargeable In a few minutes and can deliver power over a wide operating temperature range. They are used in many applications as back-up power supply, or to power autonomous sensor nodes or in applications like tracking and monitoring, smartphone peripherals, smart cards, medical devices, home and building automation, smart cities, wearables, and e-textiles.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crash Bandicoot Returns in All-new Team Based, Four vs. Four, Competitive Showdown, Crash Team Rumble™9.12.2022 06:30:00 EET | Press release
Get ready to team up and throw down, because Crash and his friends (and foes) are back, and this time there will be some unexpected, fur-ocious competition! In development by the talented team at Toys for Bob who brought fans the acclaimed Crash Bandicoot™ 4: It’s About Time™, Crash Team Rumble ™ is an all-new 4v4, team-based online multiplayer video game set in Crash Bandicoot’s vibrant and zany universe. Published by Activision Publishing, Inc., Crash Team Rumble will release on PlayStation®5, PlayStation®4, Xbox® Series X/S and Xbox One® in 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005292/en/ Crash Team Rumble Gameplay Screenshot (Photo: Business Wire) In Crash Team Rumble , fans can play as Crash, Dingodile, and a host of other friends and frenemies, each of which has their own distinct power, personality, and playstyle, as they compete across wild and varied arenas in 4v4 team-based online multiplayer a
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer9.12.2022 02:00:00 EET | Press release
Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR) positive, HER2 low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-) or HER2 negative (IHC 0) unresectable or metastatic breast cancer. Safety data were consistent with previous trials of datopotamab deruxtecan. Results were presented today as a Spotlight Poster Discussion (Abstract #PD13-08) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Approximately 70% of breast cancer tumors are considered HR positive and HER2 low or negative.1 For patients with HR positive, HER2 low or negative metastatic breast cancer that progress on or are not suitable candidates for endocrine the
TreviPay Acquires Apruve9.12.2022 01:45:00 EET | Press release
TreviPay, a leader in global B2B payments and invoicing solutions, today announced the signing of a definitive agreement to acquire payment platform Apruve. Apruve offers a robust suite of payment solutions for global enterprises that will complement and expand on TreviPay’s existing order-to-cash technology offerings, merchant invoicing solutions, and the geographical reach of TreviPay’s existing B2B networks. TreviPay has experienced unprecedented demand from global enterprise buyers and sellers resulting in 30% organic growth in 2022, and this acquisition furthers TreviPay's plans to expand its order-to-cash technology offerings and B2B payment network. This acquisition builds on TreviPay’s recent purchase of Baton Financial Services. “TreviPay provides payment and invoicing solutions for a number of leading manufacturers and OEMs; the acquisition of Apruve will accelerate our advancement in the technology manufacturing vertical and expand our geographic reach into key Asian markets
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy9.12.2022 00:05:00 EET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet its primary endpoint of overall survival (OS) at the final analysis. CONTACT-01 is a phase III clinical trial evaluating Cabometyx® (cabozantinib) in combination with atezolizumab (Tecentriq®) versus docetaxel in patients with unmutated metastatic non-small cell lung cancer (NSCLC) who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy. Howard Mayer, M.D., Executive Vice President, Head of Research and Development at Ipsen, said: “The results from the CONTACT-01 clinical trial have shown the challenge of treating NSCLC patients after prior lines of treatment have failed. While the findings of the study have not met the primary endpoint in this setting, we remain confident in the clinical efficacy of cabozantinib alone and in combination with another treatment in existing indications in difficult-to-treat tu
Verisign Reports Internet Has 349.9 Million Domain Name Registrations at the End of the Third Quarter of 20228.12.2022 23:57:00 EET | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the third quarter of 2022 closed with 349.9 million domain name registrations across all top-level domains, a decrease of 1.6 million domain name registrations, or 0.4%, compared to the second quarter of 2022.1,2 Domain name registrations have increased by 11.5 million, or 3.4%, year over year.1,2 The .com and .net TLDs had a combined total of 174.2 million domain name registrations in the domain name base3 at the end of the third quarter of 2022, a decrease of 0.2 million domain name registrations, or 0.1%, compared to the second quarter of 2022. The .com and .net TLDs had a combined increase of 2.1 million domain name registrations, or 1.2%, year over year. As of Sept. 30, 2022, the .com domain name base totaled 160.9 million domain name registrations, and the .net domain name base totaled 13.2 million domain name registrations. New .com and .net domain
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom